Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IV Study to Investigate the Safety and Effectiveness of Rivaroxaban(Xarelto) 2.5mg [BID]+Acetylsalicylic Acid(ASA) 75mg [OD] in Indian Patients With Coronary and/or Symptomatic Peripheral Artery Disease

Next Previous
X
Search
Trial Profile

A Phase IV Study to Investigate the Safety and Effectiveness of Rivaroxaban(Xarelto) 2.5mg [BID]+Acetylsalicylic Acid(ASA) 75mg [OD] in Indian Patients With Coronary and/or Symptomatic Peripheral Artery Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aspirin (Primary) ; Rivaroxaban (Primary)
  • Indications Arterial thrombosis; Cardiovascular disorders; Coronary artery disease; Peripheral arterial disorders
  • Focus Adverse reactions
  • Sponsors Bayer

    • Most Recent Events

    • 28 Jun 2024 Status changed from active, no longer recruiting to completed.
    • 28 May 2024 Planned End Date changed from 14 May 2024 to 5 Jun 2024.
    • 29 Dec 2023 Planned End Date changed from 30 Apr 2024 to 14 May 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top